SCHEMBL171036

SCHEMBL171036

Cc1cccc(S(=O)(=O)NC(C)C)c1

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.53
NLRP3 Q96P20 1/20 0.51
ALDH1A1 P00352 4/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FBP1 P09467 9/20 0.49
HPGD P15428 1/20 0.49
EDNRA P25101 1/20 0.48
HTR2B P41595 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27954290 0.83 KMT2A (0.54) KMT2AMEN1NLRP3ALDH1A1MAPT
SCHEMBL7378828 0.82 ADAMTS4 (0.59) KMT2ANLRP3ALDH1A1MAPTFBP1
Hydrochloric Acid SCHEMBL7456085 0.80 ADAMTS4 (0.57) KMT2ANLRP3ALDH1A1MAPTFBP1
SCHEMBL1906746 0.80 KMT2A (0.51) KMT2ANLRP3ALDH1A1MAPTFBP1
SCHEMBL12285828 0.80 SLC1A3 (0.53) KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL6920158 0.80 KMT2A (0.69) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL265556 0.80 HSD17B2 (0.49) ALDH1A1EDNRAHTR2B
SCHEMBL9866942 0.80 HTR2B (0.49) ALDH1A1HTR2B
SCHEMBL12376750 0.80 PGR (0.60) ALDH1A1MAPTLMNAFBP1EDNRA
SCHEMBL12089569 0.80 CA2 (0.51) NLRP3ALDH1A1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145931-A1 SMALL MOLECULE INHIBITOR FOR β-CATENIN/BCL9 PROTEIN-PROTEIN INTERACTION AND USE THEREOF 上海医药工业研究院有限公司 2024-07-11 WO disclosed
US-20160333011-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-11-17 US disclosed
US-20140378449-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-12-25 US disclosed
US-8889673-B2 Triazolopyridine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-11-18 US disclosed
US-20140038939-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-02-06 US disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 US disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
US-20120264747-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS ZHU BING-YAN (US) 2012-10-18 US disclosed
US-7589112-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2009-09-15 US disclosed
US-7556918-B2 Color photographic films comprising support having color developable light sensitive silver halide emulsion layers and color dye-forming couplers, used for high speed print reproduction; storage stability FUJIFILM CORPORATION (JP) 2009-07-07 US disclosed
US-7425408-B2 Silver halide color photographic light-sensitive material FUJIFILM CORPORATION (JP) 2008-09-16 US disclosed
US-20080113305-A1 SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL FUJIFILM CORPORATION 2008-05-15 US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
US-20070054224-A1 Silver halide color photographic light-sensitive material FUJI PHOTO FILM CO., LTD. 2007-03-08 US disclosed
US-7183044-B2 Silver halide color photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 2007-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191444-A1 Benzimidazolyl derivatives JAK1, MARK1, RAF1 KMT2A 2009/4885MEN1 1171/4885NLRP3 1606/4885
US-20140378449-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KMT2A 1888/4885MEN1 3155/4885NLRP3 942/4885
US-20160333011-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK1, JAK2, JAK3 KMT2A 1937/4885MEN1 3266/4885NLRP3 618/4885
US-20120264747-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KMT2A 1888/4885MEN1 3155/4885NLRP3 942/4885
US-20140038939-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KMT2A 1888/4885MEN1 3155/4885NLRP3 942/4885
US-20070191423-A1 Isoquinoline derivatives ABL1, MAP3K1, MAP3K2 KMT2A 1108/4885MEN1 2006/4885NLRP3 3638/4885
US-20130158076-A1 Methylene Urea Derivatives BRAF, RAF1, CMPK1 KMT2A 996/4885MEN1 549/4885NLRP3 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.